ALN-AT3SC-003: ATLAS INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B with Inhibitory Antibodies to Factor VIII or IX

This study will evaluate the efficacy and safety of fitusiran compared to on-demand treatment with bypassing agents, as determined by the frequency of bleeding episodes in enrolled adult subjects who are who have hemophilia A or B with an inhibitor who are not on prophylaxis.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Hemophilia
• Age: - 99 Years
• Gender: All